key: cord-0727253-st0u0fau authors: Ramphul, Kamleshun; Lohana, Petras; Ramphul, Yogeshwaree; Park, Yun; Mejias, Stephanie; Dhillon, Balkiranjit Kaur; Sombans, Shaheen; Verma, Renuka title: Hypertension, diabetes mellitus, and cerebrovascular disease predispose to a more severe outcome of COVID-19 date: 2021-04-12 journal: Arch Med Sci Atheroscler Dis DOI: 10.5114/amsad.2021.105255 sha: 4ed73fb7a5da150bc7f0bb0faf6484d417117dce doc_id: 727253 cord_uid: st0u0fau INTRODUCTION: The world is currently facing the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The total number of cases of coronavirus disease 2019 (COVID-19) is rising daily and no vaccine has yet been approved. While the pathophysiology behind the virus is still being studied, many possible several risk factors using small sample sizes have been found. MATERIAL AND METHODS: We conducted a pooled analysis using several databases such as Medline, Scopus, Wangfang, Web of Science, Research Square, medrxiv, and Google Scholar to identify studies reporting severe and non-severe groups of COVID-19 patients. The odds ratios as well as the 95% confidence intervals for hypertension, diabetes, and cerebrovascular disease leading to severe COVID-19 were calculated using R-software. RESULTS: Fifty-three articles were used for our analysis and they involved 30,935 confirmed cases of COVID-19 from several countries across the world. The odds ratio for severe COVID-19 in hypertensive patients, diabetics, and patients with a history of cerebrovascular disease was 2.58 (95% confidence interval (CI): 2.16–3.08, from 53 studies), 2.17 (95% CI: 1.72–2.74, from 44 studies), and 2.63 (95% CI: 1.80–3.85, from 25 studies), respectively. CONCLUSIONS: Our analysis confirms that patients with hypertension, diabetes, or cerebrovascular disease are at a higher risk of a severe outcome of COVID-19. It is thus vital for physicians to identify the main risk factors for a severe outcome of this disease. In December 2019, several patients in Wuhan, China, were admitted with symptoms of "pneumonia of unknown etiology". Over the next few days, the Chinese Centre for Disease Control and Prevention (CDC) started to investigate the possible causes of these new and strange presentations. A new virus was finally identified and found to belong to the family of coronavirus (CoV) which also included severe acute respiratory syndrome coronavirus (SARS-CoV), discovered in 2002, and the Middle East respiratory syndrome coronavirus (MERS-CoV) which appeared in 2012 [1] [2] [3] . The virus was called severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) and the disease it can cause was called coronavirus disease 2019 (COVID-19) [1] . As SARS-CoV-2 continued to spread over China and over different countries, the World Health Organization declared it as a pandemic. Almost a year later, it has infected about 85,892,625 people causing 1,857,399 deaths worldwide [1, 3, 4] . Since many countries have limited health care resources and intensive care units [3] , many researchers studied early data to find possible risk factors that can lead to a more severe outcome of this virus [1, [5] [6] [7] [8] [9] [10] [11] [12] [13] . Analysis of SARS-COV-2 showed that the virus engages the angiotensin-converting enzyme 2 (ACE2) as a receptor to penetrate human cells [14] . The enzyme is present in multiple systems including the cardiovascular system. Diabetics have marked hyperglycemia which leads to inflammatory as well as coagulation imbalance [15] , which potentiates the replication of the virus [16] . Hypertension and diabetes are also the two most important risk factors among patients with cerebrovascular disease. COVID-19 offers hypercoagulable and possible hypoxic states in some patients which could lead to more severe outcomes in patients with a prior history of cerebrovascular disease [17] . The severity of these three risk factors for the progress of COVID-19 patients was tested and confirmed using limited population groups during the first 4 months of the pandemic [12, 18, 19] . We hereby sought to expand and strengthen the understanding and risks using a larger population sample via a pooled analysis. We used the guidelines set up by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) to conduct a meta-analysis [20] (Figure 1 ). Our search team consisted of two groups. Each group first independently searched Medline, Scopus, Wangfang database, Web of Science, Research Square, medrxiv, and Google Scholar databases using the keywords "COVID-19", "coronavirus 2019", "2019-nCoV", "SARS-CoV-2", "hypertension", "diabetes", "diabetes mellitus", "cerebrovascular disease", and "stroke". Articles published between 1 st December 2019 and 15 th October 2020 were included in our selection. We were able to evaluate studies published in English, French, Chinese, and Spanish. Studies needed to report two groups: one severe and one non-severe. Based on previous studies [7, 12, 19, [21] [22] [23] [24] [25] [26] and since there are multiple guideline protocols in different countries, severity Included was defined depending on either clinical presentation during their hospitalizations and laboratory findings [27] [28] [29] [30] , admission in intensive care unit [31] , use of mechanical ventilation [32] or patients ranked using radiological findings [33] . The studies also had to include at least one of the three risk factors being studied by our team. We excluded studies that did not provide the raw table of data, case series, and case reports, meta-analyses and also had a very small sample size (n < 10). The articles that met the initial search criteria were further assessed by their abstracts and full texts. Each researcher presented his/her search results and discussed it with his/her group [22, 34, 35] . Eventually, each group made its own list and discussed together with the team to draft a final inclusion list. Disagreements were resolved by a consensus from all the researchers involved. Statistical analysis was performed using R software (version 4.0.3) (https://www.r-project.org/). We used the meta-package to study our data and a forest plot was also extrapolated [36] . The heterogeneity of our study was assessed via Higgins's I 2 test [37] . The fixed-effect model was applied if the I 2 was less than 50% and, the random-effect model was used for I 2 greater or equal to 50% for our study. The study was conducted in compliance with the Declaration of Helsinki and no ethical approval was required [38] . Our initial search yielded 12,903 studies. They were first filtered off based on the title and abstract. Finally, 592 articles were reviewed for their full texts. We initially chose 77 studies and finally after careful evaluation and further discussions, 53 articles that matched our criteria of selection for hypertension [14, 27, 28, 30, 32, 33, A total of 7,031 patients formed the severe group and 23,904 patients formed the non-severe group in our selection. 2,514 severe patients also had a history of hypertension while 3,537 patients in the non-severe group had hypertension. The odds ratio for a hypertensive patient to have a severe outcome of COVID-19 was 2.58 (95% confi-dence interval (CI): 2.16-3.08, heterogeneity: I 2 = 80%, p < 0.01) (Figure 2 ). Our analysis found 6,327 severe cases and 22,071 non-severe cases amongst which 1,622 and 2,548 had a history of diabetes, respectively with an odds ratio of 2.17 (95% CI: 1.72-2.74, heterogeneity: I 2 = 81%, p < 0.01) (Figure 3 ). Three hundred and seventy-three patients with a history of cerebrovascular disease developed a severe outcome of COVID-19 out of the 4,361 severe cases reported in total, compared to 481 of the 12,809 non-severe cases. Their odds ratio was estimated at 2.63 (95% CI: 1.80-3.85, heterogeneity: I 2 = 63%, p < 0.01) ( Figure 4 ). Our study provides an update on the impact of hypertension, diabetes, and cerebrovascular disease on the severity of COVID-19. It is one of the largest pooled analyses, to our knowledge, that includes these three risk factors. We used 53 studies that covered 30,935 confirmed cases of COVID-19 from several countries, classified as severe and non-severe ones. The findings closely confirm early studies such as the study involving 2,552 patients conducted by Lippi et al. who found that the risk of severe COVID-19 is increased by almost 2.5 with a history of hypertension [12] while Del Sole et al. reported values of 2.24 among 2,794 patients [25] . Similar higher risks have been previously linked among patients with diabetes and cerebrovascular diseases. Aggarwal et al. studied previously published reports totaling 2,564 patients and found that the odds ratio of severity among diabetes was 2.60 (95% CI: 1.96-3.45) [7] . Their team also published another early pooled analysis involving four studies and reported that patients with a prior history of cerebrovascular disease are at 2.5 higher risk of ending with a more severe outcome of COVID-19 [19] . While the increased risks of severity in patients with hypertension, diabetes, and cerebrovascular disease can now be statistically established, there are multiple theories and possible pathways concerning their pathophysiology. Huang et al. suggested that there may be an imbalance of various inflammatory cytokines in COVID-19 which may be more severe in hypertensive patients. Higher levels of multiple factors such as IL-6, IL-7, and granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor α have also been reported to be involved in the various pathophys- Heterogeneity I 2 = 81%, t 2 = 0.3521, p < 0.01 iologic pathways of hypertension. Their presence in COVID-19 patients can thus trigger a more severe outcome and also increase the risk of cytokine storms [14, 86, 87] . The possible link between the Renin-Angiotensin-Aldosterone System and COVID-19 has also been suggested [88] . The SARS-CoV-2 has an S spike protein (S-protein) that can bind to ACE2 receptors [89] . This allows the virus to enter the host cells. The viral and receptor complex is then endocytosed. This eventually leads to a lower number of the receptors and a higher level of Angiotensin II [90] . Several very similar pathways have also been hypothesized for diabetic patients. The higher levels of multiple pro-inflammatory conditions and the often co-accompanying obesity with diabetes can both lead to a more severe progression of COVID-19 [7, 91] . A study by Barron et al. found that there was also a higher risk of mortality in both type 1 and type 2 diabetics who were diagnosed with COVID-19 [92] . In their analysis, Wang et al. hypothesized that since the surfactant production and the vascular beds in diabetics are often affected, they typically have a poor pulmonary function [93] . They also hypothesized that the high sugar level and lower insulin level can affect mul-tiple innate immune responses that can lead to an impaired function of cells responsible for improving an immune protection in the alveoli and impact the proper formation of Th1 and Th2 cells. These make diabetics more prone to multiple pulmonary infections as they will have a slower and weaker response to combat them [93] [94] [95] [96] [97] [98] [99] [100] [101] . Further research should also be encouraged from hospitals to publish data on diabetics having different anti-diabetic treatments so that the relationship between antidiabetic treatments and severity of COVID-19 can also be explored in the future [102] . During the pre-COVID-19 era, several patient groups were also associated with higher risks and worse outcome of diabetic ketoacidosis [103] . Research comparing changes in severity and mortality in those specific patient groups can also help physicians prioritize their resources for a better clinical outcome. The higher risks of severe COVID-19 in patients with a history of cerebrovascular disease have been linked with several possible pathophysiological pathways. Most stroke patients have underlying conditions such as diabetes and hypertension. They are also chronically using multiple drugs that can lead to multiple pathways in the pathogenesis of SARS-CoV-2. Several cases of new onset of stroke [104] . Fifi et al. warned that there are many new cases of stroke in young patients who initially presented with mild respiratory symptoms [105] . As COVID-19 is associated with multiple laboratory changes that can predispose previous and new patients with cerebrovascular insults, physicians need to be on the watch-out for neurological changes and symptoms [106] [107] [108] . Since COVID-19 is a new disease, the progress in understanding the impact and risk factors, as well as changes in management protocols of atrisk patients, have been done in a step-by-step manner based on findings from multiple cellular studies and pooled analyses. Initially, there were several arguments for and against the continued use of ACEI and ARBs among hypertensive patients, diabetics and also patients with a history of cerebrovascular disease [109, 110] . Both the European Society of Hypertension and the American Heart Association advised that these medications should not be discontinued as the benefits outweigh the risks [111] . Protocols involving the use and effects of corticosteroids among diabetics were also evaluated. High doses lead to a rise in blood glucose levels in up to 80% of diabetics who were COVID-19 positive and were associated with a higher mortality rate. With the higher severity of COVID-19, the use of anti-diabetic medications such as DPP4 Inhibitors and their effects are currently being studied [112] [113] [114] . While multiple changes have been established in the effective management of new cases of stroke in COVID-19 positive patients, guidelines for COVID-19 patients with a past history of cerebrovascular disease have followed the hypertensive and the diabetic protocols due to their close relationship in the pathophysiology [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] . In conclusion, our study provided a fresh view with a larger sample size on three main risk factors that can cause COVID-19 patients to have a severe outcome from the disease. We strongly believe that these preliminary reports can help physicians prioritize their limited healthcare resources and be prepared in advance for any severe outcome of the disease. Coronavirus disease: a review of a new threat to public health Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19) Tackling the COVID-19 pandemic in paradise: the Mauritian experience COVID-19 Coronavirus Pandemic 2020 Updates on laboratory investigations in coronavirus disease 2019 (COVID-19) Acute kidney injury is associated with worse prognosis in COVID-19 patients: a systematic review and meta-analysis Diabetes mellitus association with coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis Lymphopenia and neutrophilia at admission predicts severity and mortality in patients with COVID-19: a meta-analysis Red blood cell distribution is a significant predictor of severe illness in coronavirus disease 2019 Eosinophil count in severe coronavirus disease 2019 Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis Headache may not be linked with severity of coronavirus disease 2019 (COVID-19) COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study COVID-19 and diabetes: knowledge in progress COVID-19 and diabetes mellitus: from pathophysiology to clinical management Influence of COVID-19 on cerebrovascular disease and its possible mechanism. Neuropsychiatr Sanchis-Gomar F. Diabetes mellitus association with coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): a pooled analysis of published literature Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: a pooled analysis Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -a systematic review, meta-analysis, and meta-regression Features of severe COVID-19: a systematic review and meta-analysis Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression Clinical characteristics of hospitalized patients with COVID-19 in Sofia Clinical characteristics of 276 hospitalized patients with coronavirus disease COVID-19 Statements & Official Documents 2020 Epidemiological and clinical characteristics of 333 confirmed cases with coronavirus disease Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia JBI Manual for Evidence Synthesis Study Quality Assessment Tools 2020 How to perform a meta-analysis with R: a practical tutorial Measuring inconsistency in meta-analyses World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China Clinical characteristics and prognosis of 244 cardiovascular patients suffering from coronavirus disease in Wuhan, China Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan The clinical and chest CT features associated with severe and critical COVID-19 pneumonia Epidemiological and clinical characteristics of coronavirus disease 2019 in Daegu, South Korea Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center study Predictors for severe COVID-19 infection Clinical features and outcomes of 105 hospitalized patients with covid-19 in COVID-19 in a designated infectious diseases hospital outside Hubei Province, China Clinical characteristics of Coronavirus disease 2019 patients in Beijing, China Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19 Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19 Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia Predictors of severity in Covid-19 patients in Casablanca Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19 Clinical characteristics of coronavirus disease 2019 in China Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China Predictors of coronavirus disease 2019 severity: a retrospective study of 64 cases Clinical characteristics of SARS-coV-2 infections involving 325 hospitalized patients outside Wuhan Clinical characteristics of 312 hospitalized older patients with COVID-19 in Wuhan Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Risk factors for developing into critical COVID-19 patients in Wuhan, China: a multicenter, retrospective, cohort study Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease Clinical epidemiology of hospitalized patients with COVID-19 in Japan: report of the COVID-19 REGISTRY JAPAN Model-based prediction of critical illness in hospitalized patients with COVID-19 Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019 Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China Clinical features and shortterm outcomes of 221 patients with COVID-19 in Wuhan Epidemiological and clinical characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a single-center experience Impact of comorbidities on patients with COVID-19: a large retrospective study in Zhejiang A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients Analysis of clinical characteristics of 49 patients with coronavirus disease Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China Clinical characteristics of patients infected with the novel 2019 coronavirus (SARS-Cov-2) in Guangzhou Clinical characteristics and outcomes of 421 patients with coronavirus disease 2019 treated in a Mobile Cabin Hospital Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Epidemiological and clinical course of 483 patients with COVID-19 in Wuhan, China: a single-center, retrospective study from the mobile cabin hospital Clinical features and treatment of COVID-19 patients in northeast Chongqing Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Immune mechanisms of hypertension SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions COVID-19 and Hypertension: What We Know and Don't Know 2020 COVID-19: consider cytokine storm syndromes and immunosuppression Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study Impacts of type 2 diabetes on disease severity, therapeutic effect, and mortality of patients with COVID-19 Relationship between diabetes and respiratory diseases -clinical and therapeutic aspects Relevance of non-communicable comorbidities for the development of the severe forms of dengue: a systematic literature review Inflammation and oxidative stress markers in diabetes and hypertension Connecting type 1 and type 2 diabetes through innate immunity Apoptosis, vascular leakage and increased risk of severe dengue in a type 2 diabetes mellitus patient Is diabetes a risk factor for a severe clinical presentation of dengue? Review and meta-analysis Tuberculosis and diabetes mellitus: convergence of two epidemics Vascular endothelial function and hypertension: insights and directions The COVID-19 pandemic and diabetes mellitus An Update on the incidence and burden of diabetic ketoacidosis in the U.S. Diabetes Care Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza COVID-19 related stroke in young individuals D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis Neurological associations of COVID-19 How COVID-19 can damage the brain Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Antihypertensive drugs and risk of COVID-19? Managing hypertension during the COVID-19 pandemic Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2 Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study Stroke management pathway during COVID-19 pandemic scientific statement by the Saudi Stroke Society Acute stroke management pathway during Coronavirus-19 pandemic COVID-19 associated ischemic stroke and hemorrhagic stroke: incidence, potential pathological mechanism, and management Ischemic stroke in COVID-19: an urgent need for early identification and management Preserving stroke care during the COVID-19 pandemic: potential issues and solutions Acute ischemic stroke in COVID-19: putative mechanisms, clinical characteristics, and management Management of acute ischemic stroke in patients with COVID-19 infection: report of an international panel Preserving stroke care during the COVID-19 pandemic: potential issues and solutions The SARS-CoV-2/COVID-19 pandemic and challenges in stroke care in India Stroke care during the COVID-19 pandemic: experience from three large European countries The authors declare no conflict of interest.R e f e r e n c e s